Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C

Journal of Hepatology

Volumn 36, Issue 5, 2002, Pages 672-680

  De Lédinghen, Victor ^a   Trimoulet, Pascale ^a   Winnock, Maria ^b   Foucher, Juliette ^a,c   Bourlière, Marc ^d   Desmorat, Hervé ^e   Canva, Valérie ^f   Capron, Dominique ^g   Lévy, Stéphane ^h   Mion, François ⁱ   Mannant, Paul Régis ^j   Chêne, Geneviève ^b   Fleury, Hervé ^a   Couzigou, Patrice ^a   Bernard, Pierre Henri ^c  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d HÔPITAL SAINT JOSEPH   (France)

^e Clinique du Parc   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

^h REIMS UNIVERSITY HOSPITAL   (France)

ⁱ HOSPICES CIVILS DE LYON   (France)

^j Clinique Bordeaux Nord   (France)

more..

Author keywords

Anti viral therapy; Chronic hepatitis; Cirrhosis; Daily interferon; Hepatitis C; Induction dose; Interferon; Ribavirin

Indexed keywords

REBETRON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRION; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOPSY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0036264550     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00026-0     Document Type: Article

References (19)

1. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
2. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
3. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
4. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
5. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
6. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy
7. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
8. Dose-dependent acute clearance of hepatitis genotype 1 virus with interferon alfa
9. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo
10. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: Definition of optical conditions for specimen collection and clinical application in interferon-treated patients
11. An algorithm for the grading of activity in chronic hepatitis C: The METAVIR Cooperative Study Group
12. Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
13. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
14. Efficacy and tolerance of a 6-month treatment course of daily interferon-α2a for chronic hepatitis C with cirrhosis
15. Comparison of thrice weekly and daily human leucocyte interferon-α therapy for chronic hepatitis C
16. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: Pretreatment stratification by viral burden and genotype
17. Estimation of early hepatitis C viral clearance in patients receiving interferon and ribavirin therapy using a mathematical model
18. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
19. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy